secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001070081-26-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q1 revenue $273M, raises FY product revenue guidance to $750-850M
--------------------------------------------------------------------------------

- Q1 2026 total revenue $273M; product revenue $226M, up 47% YoY.
- Net loss $2.8M vs net income $866.6M in Q1 2025 (prior year included non-recurring gain).
- Sephience revenue $124.6M, up 36% QoQ; 1,244 patients on commercial therapy globally.
- FY 2026 product revenue guidance raised to $750-850M; total revenue expected $1.08-1.18B.
- Positive votoplam PIVOT-HD data; $50M milestone from Novartis triggered in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/0001070081-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/tmb-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer